Torque Therapeutics Stock

torquetx.comHealthcare / BioTech & PharmaFounded: 2015Funding to Date: $84.27MM

Developer of an online platform intended to provide immunotherapy services. The company is focused on the specific modulation of immune cell subsets based on novel platform technologies to address intractable cancers, particularly solid tumors, enabling doctors to get new cell therapy cures for cancer.

Register for Details

For more details on financing and valuation for Torque Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Torque Therapeutics.

Register Today


Management Team

Bart Henderson
Co-Founder, President & Board Member
Thomas Andresen Ph.D
Co-Founder and Chief Scientific Officer
Stephen Hodi MD
Scientific Advisory Board Member
Doug Cole MD
John Cox
Chief Executive Officer & Board Member
Douglas Jones
Darrell Irvine Ph.D
Sok Cheng Soh
Chief Financial Officer
Jennifer Camacho JD
Chief Legal Officer
Becker Hewes MD
Chief Medical Officer

Board Members

Doug Cole MD
John Dineen
Douglas Lauffenburger Ph.D
John Cox
Bart Henderson
John Hohneker MD

Other companies like Torque Therapeutics in the BioTech & Pharma sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation

News Highlights

Torque Therapeutics Announces the Appointment of John Cox as Chief Executive Officer
Torque Therapeutics, a clinical stage, product-platform company developing proprietary, first-in-class Deep Primed™ adoptive cell transfer therapeutic
Xconomy: With $25M, Torque Aims for a More Targeted Cell Therapy for Cancer
Genetic engineering a patient’s own immune cells to make them better cancer fighters is the latest tool in oncology, following FDA approvals of two such
Updated on: Oct 4, 2023


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.